A simple HPLC-UV Method for Therapeutic Drug Monitoring of Linezolid in human Plasma in low-resourced settings

Vijayakumar A1, Sudha V1, Alffenaar JW2,3,4, Jeyakumar SM1, Hemanth Kumar AK1*

1ICMR-National Institute for Research in Tuberculosis, Chennai 600031, India.
2University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, Australia.
3Westmead Hospital, Westmead, Australia.
4Marie Bashir Institute of Infectious Diseases, University of Sydney, Sydney, Australia.

*Correspondence: Department of Clinical Pharmacology, ICMR-National Institute for Research in Tuberculosis, Chennai, India. Phone: + 91 44 2836 9500. Email: akhemanth20@gmail.com

OBJECTIVE: A high-performance liquid chromatography method for the estimation of Linezolid in human plasma was developed and validated.

METHODS: Samples (100 µL) were deproteinized with acetonitrile and analyzed using LiChrospher 100, RP18e column with PDA detection at 254 nm. The flow rate of the isocratic mobile phase comprising of 0.1% formic acid in 1000 ml of water and acetonitrile in the ratio of 60:40 (v/v) was set at 1.0 ml/min.

RESULTS: The calibration curve ranged from 0.50 to 20.0 µg/ml and was linear. The recovery ranged from 96% to 101%. The accuracy ranged from 98 to 101% and intra- and inter-day relative standard deviation was <4.58%. The method reliably eliminated interfering materials from plasma and R² was 0.9973. The method described was applied to the determination of plasma LZD concentration in multi-drug-resistant tuberculosis patients who are treated with a dose of 600 mg LZD once daily.

CONCLUSIONS: The developed method is suitable for determination of plasma LZD in routine care and considered feasible in less-resourced settings.

KEYWORDS: Linezolid, HPLC, Method validation, Plasma, Therapeutic Drug Monitoring.

INTRODUCTION
Drug-resistant tuberculosis (TB) continues to be a public health threat. Worldwide in 2019, close to half a million people developed rifampicin-resistant TB (RR-TB), of which 78% had multidrug-resistant TB (MDR-TB). The three countries with the largest share of the global burden were India (27%), China (14%), and the Russian Federation (8%) [1]. Development of MDR TB could be due to a variety of reasons including microbial, clinical, or programmatic issues. According to the drug-resistance survey report, in India 2014–2016, 28% of patients with TB have resistance to any anti-tubercular drugs and 6.2% have MDR-TB; among MDR-TB,
21.8% have pre-extremely drug-resistant (XDR-TB) and 1.3% have XDR-TB [2]. Pre-XDR TB is caused by Mycobacterium tuberculosis (M. tuberculosis) strains that fulfill the definition of MDR/RR-TB and which are also resistant to any fluoroquinolone. Preferably a treatment regimen for MDR-TB consists of WHO Group A category drugs including linezolid (LZD), bedaquiline, and fluoroquinolone (levofloxacin or moxifloxacin). Group A drugs are considered to be highly effective against MDR-TB. The treatment regimen is completed with WHO Group B drugs, i.e. clofazimine and cycloserine (or terizidone) [3]. Linezolid, an oxazolidinone antibiotic that binds to the 50S ribosomal subunit inhibiting protein synthesis, is a repurposed drug as it was originally developed for infections caused by susceptible Gram-positive bacteria like community-acquired pneumonia or skin and soft tissue infections [4]. After proven in vitro activity against Mycobacterium tuberculosis [5] it has been increasingly used for MDR-TB treatment and has been associated with good treatment outcomes. Success rates of 68% up to 82% encourage physicians to use these drugs as part of routine care [6,7]. However, prolonged use, beyond the licensed treatment duration of 28 days, has shown that the drug is not well tolerated, and severe adverse effects occur frequently and include anemia, neuropathy and lactic acidosis prompting cessation of treatment [8]. To reduce toxicity therapeutic drug monitoring (TDM) has been recommended in international guidelines [9,10]. Trough concentrations exceeding 8 mg/l are associated with toxicity [11] and for prolonged treatment trough concentrations should be even lower to prevent toxicity [12]. On the other hand, to prevent development of resistance or treatment failure, too low drug concentrations should be avoided. As a target for efficacy, an area under the concentration-time curve (AUC) to the minimal inhibitory concentration (MIC) ratio of at least 119 has been established [13]. To facilitate TDM there is a need for a simple assay suitable for TB endemic areas. As linezolid is a core drug for MDR-TB, it has been recommended that access to assays should be available at regional level to facilitate a short turn-around time and reduce sample shipment [14]. To operate assays at a regional level in high burdened TB countries, challenges regarding procurement costs, availability of skilled laboratory scientists, and sample logistics need to be overcome.

Several analytical methods for linezolid estimation in plasma, serum, saliva, and dried blood spot have been described in literature [15-20]. Most of them use a chromatographic separation of analytes followed by diverse methods of detection like UV spectrophotometry or tandem mass spectrometry. Compared to high-performance liquid chromatography (HPLC), liquid chromatography-tandem mass spectrometry (LC-MS/MS) is quite expensive, requires more skilled laboratory scientists and requires a more advanced and reliable laboratory infrastructure (e.g. collision gas for the mass spectrometry). These may not be affordable or available in resource-poor settings [15]. HPLC methods for the determination of LZD in plasma and saliva were also reported [16-20]. Since LZD is used in combination with at least 3 other second-line anti-TB drugs and several other drugs in case of co-morbidities like diabetes or co-infections like HIV, it is essential to establish the specificity of the analytical method in order to rule out interference of these drugs in the estimation of LZD in plasma before it can be used in clinical practice. Therefore, we developed and validated a simple, selective, and sensitive HPLC method for the determination of LZD in plasma, to facilitate routine TDM in MDR-TB programmatic treatment.

**MATERIALS AND METHODS**

**Chemicals and reagents**

LZD drug substance (>98%) was obtained from Sigma Aldrich. Acetonitrile (Merck), and formic acid were purchased from Qualigens, India. Deionized water was processed through a water purification system (Merck Millipore, Germany). Pooled human plasma was obtained from a Blood Bank, Chennai, India. All chemicals used were of HPLC grade.
Chromatographic system
The HPLC system, Prominence 1 (Shimadzu Corporation, Kyoto, Japan) comprised of two pumps (LC-2030-3D), photodiode array detector (SPD-20AV) with built-in autosampler and system controller. Data collection and acquisition were carried out using Shimadzu Lab solution software. LiChrospher 100, Lichro CART 250-4 RP18 e (5µm) particle size (Merck, Germany) was used as the analytical column. An isocratic mobile phase was prepared by mixing 0.1% formic acid in 1000 ml of water and acetonitrile in the ratio of 60:40 (v/v). The solvents were degassed individually using a Millipore vacuum pump before preparing the mobile phase. Each chromatogram was run for 5 minutes at a flow rate of 1.0 ml/min at 40°C, with the PDA detector set at a wavelength of 254 nm. Unknown concentrations were calculated from linear regression analysis vs LZD concentration curve; linearity was verified using estimates of correlation coefficient (r).

Preparation of standard solution
To prepare a stock solution (1mg/ml), LZD was dissolved in Milli-Q water. Working standard concentrations ranging from 0.50 to 20 µg/ml were freshly prepared in pooled plasma by spiking with the stock solution. These concentrations span the range of clinical interest for commonly prescribed dose for LZD for MDR-TB [11].

Sample preparation
To 100 µl of each of the calibration standards and test plasma samples, 200 µl of acetonitrile was added and mixed vigorously on a vortex mixer, followed by centrifugation at 6720 x g for 10 min. The clear supernatant (200 µl) was evaporated in a nitrogen evaporator to dryness at room temperature. The dried residue was reconstituted in 100 µl of the mobile phase and 50 µl was injected into the HPLC column.

Method validation
The accuracy and linearity of LZD standard concentrations were determined by analyzing a set of standard solutions with concentrations ranging from 0.50 to 20.0 µg/ml. The within-day and between-day variations were evaluated by processing each LZD standard concentration in triplicate for six consecutive days. The precision of the analytical method was determined by analyzing plasma samples containing varying concentrations of LZD in duplicate on three consecutive days. The specificity of the analytical method was established by ruling out interference of certain anti-TB (rifampicin, isoniazid, pyrazinamide, ethambutol, ethionamide, cycloserine, levofloxacin, ofloxacin, moxifloxacin, rifabutin, rifampentine, bedaquiline, delamanidlofazamine), anti-retroviral (nevirapine, efavirenz, zidovudine, didanosine, stavudine, lamivudine, ritonavir, tenofovir) and anti-diabetic (metformin and sulphonylureas) drugs in the method described. All the drugs were evaluated at a concentration of 10 µg/ml. Interference due to endogenous compounds was also investigated by analyzing blank plasma samples. In order to assess the recovery of LZD from plasma, different concentrations of LZD (0.50, 2.5, 5.0, and 10.0 µg/ml) were prepared in pooled human plasma to which known concentrations of LZD were added. The percent recovery of LZD from plasma, different concentrations of LZD (0.50, 2.5, 5.0, and 10.0 µg/ml) were prepared in pooled human plasma to which known concentrations of LZD were added. The percent recovery of LZD from plasma was calculated by dividing the difference in LZD concentrations by the added concentration. Recovery experiments were carried out on three different days. Limits of detection (LOD) and quantitation (LOQ) were estimated mathematically from the standard curve equations. LOD was calculated using the formula 3.3 x σ/S, where σ is the standard deviation of Y – axis intercepts and S is the slope of the calibration curve. LOQ was calculated using the formula 10.0 x σ/S, where σ is the standard deviation of Y – axis intercepts and S is the slope of the calibration curve. Carryover has always been a problem and therefore blank plasma samples were injected after every five samples that contain the highest concentration. Thereby sample leftover from a previous injection that may interfere or coelute with analyte of interest can be prevented. Method validation was carried out as per International conference of
Figure 1. Representative chromatogram of extracted LZD plasma standard 20 ug/ml.

Figure 2. Representative chromatogram of extracted LZD plasma standard 0.50 ug/ml.

Figure 3. Representative chromatogram of extracted LZD plasma from a patient sample.
Measurement of clinical samples

The method described was applied to the determination of LZD concentration in plasma from 5 patients who are treated with a dose of 600 mg LZD along with other second-line anti-TB drugs in an ongoing clinical study at NIRT (IEC no. 2018017). Serial venous blood samples were collected at pre-dose and at 1, 2, 4, 6, 8, 12, and 24 hours after drug administration. Blood samples were centrifuged at 3500 x g and plasma was stored at -80°C until analyses.

RESULTS

Validation

LZD was well separated and seen as a discrete peak. The representative chromatograms of extracted LZD standards 20.0 and 0.50 µg/ml and an extracted plasma sample from MDR-TB patient are given in (Figures 1–3) with a retention time of 3.1 min. Blank plasma sample did not give any peak at the retention time of LZD (Figure 4).

In the present method, LZD concentrations ranging from 0.50 to 20.0 µg/ml were checked for linearity. Calibration curve parameters of LZD from six individual experiments for

| Standard concentration (µg/ml) | Mean height + SD (%RSD) |
|-------------------------------|------------------------|
|                               | Within day (n=3)       | Between day (n=6)   |
| 0.5                           | 6294 ± 269.77 (4.29)   | 6237.5 ± 229.49 (3.68) |
| 1                             | 13168 ± 602.97 (4.58)  | 12998.7 ± 444.13 (3.42) |
| 2.5                           | 33034 ± 1147.5 (3.47)  | 32285.7 ± 404.21 (1.25) |
| 5                             | 65644 ± 1912.59 (2.91) | 66893.3 ± 785.5 (1.17) |
| 10                            | 133479 ± 3446.98 (2.58)| 131683.3 ± 2809.68 (2.13) |
| 20                            | 267180 ± 6656.75 (2.49)| 261155.3 ± 6656.75 (1.98) |
standard concentrations ranging from 0.50 to 20.0 µg/ml showed a linear relationship (Figure 5). The mean correlation coefficient (R), coefficient of determinants (R²), slope and intercept values were 0.9986, 0.9973, 12823, and 3786 respectively. The linearity and reproducibility of the various standards used for constructing calibration graphs for plasma LZD were given in Table 1. The intra- and inter-day relative standard deviation for standards containing 0.50 – 20.0 µg/ml ranged from 2.49% to 4.58% and 1.17% to 3.68% respectively. The accuracy of plasma LZD concentrations ranged from 98 to 101%. The precision of the method was further evaluated by analyzing plasma samples containing different concentrations of LZD with corresponding RSD ranging from 1.41 to 3.21% and the method reliably eliminated interfering materials from plasma, yielding a recovery of LZD that ranged from 96% to 101% (Table 2). The LOD and LOQ estimated mathematically

![Calibration graph for plasma LZD concentrations (0.50 – 20 ug/ml).](image)

**Figure 5.** Calibration graph for plasma LZD concentrations (0.50 – 20 ug/ml).

| Actual concentration (µg/ml) | Precision Found concentration (µg/ml) mean ± SD | % RSD | Base | Added (µg/ml) | Actual (µg/ml) | Obtained (µg/ml) | Recovery (%) |
|-----------------------------|-----------------------------------------------|-------|------|---------------|----------------|-----------------|--------------|
| 0.5                         | 0.49 ± 0.02                                  | 3.21  | 0.5  | 1             | 0.75           | 0.74            | 99           |
| 1                           | 0.99 ± 0.02                                  | 2.43  |      |               |                |                 |              |
| 2.5                         | 2.50 ± 0.06                                  | 2.29  | 2.5  | 5             | 3.75           | 3.78            | 101          |
| 5                           | 5.04 ± 0.13                                  | 2.58  |      |               |                |                 |              |
| 10                          | 10.08 ± 0.21                                 | 2.09  | 10   | 20            | 15             | 14.45           | 96           |
| 20                          | 19.91 ± 0.28                                 | 1.41  | 10   | 20            |                |                 |              |

**Table 2.** Precision & Recovery.
from the standard curve equation were 0.25 and 0.50 µg/ml respectively.

**Clinical samples**

**Figure 6** shows the pharmacokinetic profile of plasma LZD concentrations at different time points. The measured concentrations fell within the pre-defined analytical range.

**DISCUSSION**

Although LC-MS/MS is considered the preferred platform for routine TDM because of the sensitivity and specificity, the instrument is neither affordable nor feasible to operate in many resource-poor settings. As costs and availability of chemicals and reagents are keys in low-resourced settings, we included these considerations in our method development. Therefore, we developed a method for the estimation of LZD using an affordable HPLC-UV system with the linearity ranging from 0.50 µg/ml to 20 µg/ml suitable for clinical practice. Having a very low LOQ is not relevant for most drugs when applying an assay for a therapeutic doses as concentrations will be much higher at therapeutic dose at steady-state conditions. The proposed method requires 100 µl of plasma when compared to other methods where the plasma sample of 200 µl is required allowing for standardization in the lab which reduces the need for multiple precise pipettes and corresponding consumables. The HPLC method described by Shuuji Hara et al. used a mixture of acetonitrile, tetrahydrofuran, and ammonium acetate buffer as the mobile phase [16]. We applied a similar strategy for the selection of the column, i.e. a simple C18 column, to avoid the need for more expensive columns as described earlier [17]. The sample preparation in the developed method was also very simple involving single-step protein precipitation with acetonitrile. Protein precipitation can be preferred over liquid-liquid extraction using ethyl acetate [18] as it was faster which allows for routine TDM in high burdened TB settings. The use of methanol and dichloromethane liquid-liquid extraction may improve the sensitivity of the method as had been shown earlier by Traunmuller and colleagues [19]. The LOQ of their assay was 0.05 µg/ml which is 10-fold lower than our assay. However, such a low LOQ is not required for the intended purpose of TDM in MDR-TB treatment as linezolid trough concentrations typically range between 2-8 µg/ml [11,12]. Fortuna et al., used solid-phase extraction cartridges which also resulted in a lower LOQ but was time-consuming, increased cost [17]. In case of backorders and unreliable
logistics of consumables, every additional step increases the risk of not being able to run the assay routinely. Our assay had a relatively short runtime with the retention time of LZD being 3.1 minutes thereby facilitating to process a large number of samples. We did not perform an extensive sample stability study as linezolid stability in plasma and serum has been extensively studied, including freeze-thaw cycle [22] showing that linezolid samples were stable for at least 36h at room temperature. A study by showed similar results for a test period of 3 days at room temperature (100.5-104.0%) [17]. Samples could also be stored for 60 days in the refrigerator without any concern for stability (102.6 ± 0.7%) reducing the need for more expensive storage at -80°C [23]. Plasma spiked standards and samples collected from the patients were stored at -80°C and found to be stable for more than 30 days. Although we tested a significant number of potential drugs that are typically co-administered it could happen that patients use other drugs that have not been included in the inference test. Routine TDM of linezolid does not require a complete pharmacokinetic profile as we carried out in our study, but by collecting samples at trough and peak levels to calculate an AUC [24].

CONCLUSION
This RP-HPLC method for assay of LZD in plasma was developed and validated. This method spans the relevant clinical range for LZD (0.50-20.0 µg/ml) and was specific, simple, and rapid. The developed method may be suitable for the determination of plasma LZD in routine practice and considered feasible in less-resourced settings.

ACKNOWLEDGMENT
The authors gratefully acknowledge the Director, ICMR-NIRT, Dr. C. Padmapriyadarsini for providing funds for methodology development and samples for method application from BEAT study (IEC no. 2018017). Technical assistance rendered by Mr. T. Bharathiraja and Mr. V. Tamilharasan is acknowledged.

REFERENCES
1. World Health Organization, Global tuberculosis report 2020, Geneva. (2020). Available at https://www.who.int/publications/i/item/9789240013131
2. Mishra GP, Mulani JD. First national anti-tuberculosis drug resistance survey (NDRS) from india-an eye opener. J Infect 1(2), 26-29 (2018).
3. Chaudhuri AD. Recent changes in guidelines on programmatic management of drug resistant tuberculosis in India 2019: a paradigm shift in tuberculosis control. J Assoc Chest Physicians 8, 53 (2019).
4. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 358, 1975-1982 (2001).
5. Rodriguez J, Ruiz M, Lopez M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 20, 464-467 (2002).
6. Cox H, Ford N, Hughes J, Goemaere E. Linezolid for multidrug-resistant tuberculosis. Lancet Infect Dis 13(1), 16 (2013).
7. Sotgiu G, Centis R, D’Ambrosio L, Spanello A, Migliori GB. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J 42, 288-290 (2013).
8. Sotgiu GR, Centis L, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 40, 1430-1442 (2012).
9. Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med 200, e93-e142 (2019).
10. World Health Organization. WHO consolidated guidelines on drug-resistant...
tuberculosis treatment, Geneva (2019). Available at https://apps.who.int/iris/rest/bitstreams/1211676/retrieve

11. Cattaneo D, Alffenaar JW, Neely M. Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones. Expert Opin Drug Metab Toxicol 12, 533-544 (2016).

12. Bolhuis MS, Van der Werf TS, Kerstjens HA, et al. Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules. Eur Respir J 54 (2019).

13. Srivastava S, Magombbedze G, Koeuth T, et al. Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis. Antimicrob Agents Chemother 61, e00751-00717 (2017).

14. Alffenaar J-WC, Gumbo T, Dooley KE, et al. Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis. Clin Infect Dis 70, 1774-1780 (2020).

15. Kim HY, Hveysell SK, Mpagama S, Marais BJ, Alffenaar JW. Challenging the management of drug-resistant tuberculosis. Lancet 395, 783 (2020).

16. Hara S, Uchiyama M, Yoshinari M, et al. A simple high-performance liquid chromatography for the determination of linezolid in human plasma and saliva. Biomed Chromatogr 29, 1428-1431 (2015).

17. Fortuna S, De Pascale G, Ragazzoni E, Antonelli M, Navarra P. Validation of a new HPLC UV method for determination of the antibiotic linezolid in human plasma and in bronchoalveolar lavage. Biomed Chromatogr 27, 1489-1496 (2013).

18. Bolhuis M, Van Altena R, Van Hateren K, et al. Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 57, 3676-3680 (2013).

19. Traunmüller F, Mauric O, Popovic M, Joukhadar C. Rapid and sensitive determination of the antibiotic linezolid in low plasma volumes by high-performance liquid chromatography. J Chromatogr Sci 48, 325-327 (2010).

20. Cios A, Ku K, Szymura-Oleksiak J. Determination of linezolid in human serum by reversed-phase high performance liquid chromatography with ultra violet and diode array detection. Acta Pol Pharm 70(4), 631-641 (2013).

21. Guideline, ICH Harmonised Tripartite. Validation of analytical procedures: text and methodology. Q2 (R1) (2005). Available at https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf

22. Harmelink JW, Wessels MA, Greijdanus B, Uges DR. Rapid and sensitive liquid chromatography—tandem mass spectrometry method for the determination of linezolid in human serum. EAHP-S 14, 3-7 (2008).

23. Zander J, Maier B, Zoller M, Teupser D, Vogeser M. Quantification of linezolid in serum by LC-MS/MS using semi-automated sample preparation and isotope dilution internal standardization. Clin Chem Lab Med 52, 381-389 (2014).

24. Kamp J, Bolhuis MS, Tiberi S, et al. Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. Int J Antimicrob Agents 49, 688-694 (2017).